Ozempic maker Novo Nordisk on Wednesday said data showed its hotly anticipated weight loss pill prompts greater and more rapid weight loss than its blockbuster treatment Wegovy, amid competition ...

After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide) are starting to get back on track. Novo’s semaglutide cut the ...

Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the US government’s Medicare program ...

Sept 23 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's ...

The CEO of Novo Nordisk plans to blame drug middlemen for the high cost of popular diabetes and weight loss drugs Ozempic and Wegovy during a Senate hearing Wednesday ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk A/S’s Wegovy reduced deaths and illness from Covid in a large study that took place during the pandemic, more evidence of the blockbuster shot’s benefits beyond weight loss.

Novo Nordisk’s CEO testified Tuesday that the company has little control over what patients pay for its blockbuster diabetes and weight-loss drugs as skeptical senators criticized the Danish ...

Sept 2 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...